The year 2014 marked the twentieth anniversary of the discovery of the breast cancer susceptibility gene, BRCA1.1, 2 Since this discovery, our understanding of pathogenic BRCA variants and the associated increase in lifetime cancer risks has advanced significantly.3, 4 National guidelines have been developed to help clinicians identify patients with an increased risk of pathogenic BRCA mutations, and genetic counselling for risk assessment is now a routine practice.5, 6 The evolution of genetic counselling models has placed increasing importance on the use of multidisciplinary health-care teams, including medical geneticists, genetic counsellors, gynaecologists, surgeons, radiotherapists, medical oncologists and all other professionals involved in a patient’s management. There has also been a surge of technological advances and new strategies allowing for the rapid turnaround of BRCA1 and BRCA2 mutation testing. In addition, evaluation of BRCA and other BRCA-like deleterious mutations as potentially actionable tumour targets are underway, such as the development of poly(ADP)-ribose polymerase (PARP) inhibitors in classes four or five BRCA mutation-positive cancers.7, 8, 9 The present supplement contains review articles based on presentations from a scientific symposium focused on the evolving BRCA testing landscape (BRCA to the future: towards best testing practice in the era of personalised healthcare) held at the European Human Genetics Conference in Milan, June 2014.
In the first review, Professor Dominique Stoppa-Lyonnet discusses the biological effects and clinical implications of pathogenic BRCA mutations. BRCA1 and BRCA2 have key roles in the repair of DNA double-strand breaks via the mechanism of homologous recombination (HR) and ensure genome stability.10, 11, 12, 13 Germline deleterious mutations in BRCA1 or BRCA2 are associated with elevated risk of developing breast and/or ovarian cancer, sometimes with a genotype–phenotype correlation.3, 4, 14 BRCA pathogenic mutation-positive ovarian or breast cancers are susceptible to inhibitors of additional DNA damage repair pathways, such as PARP inhibitors.7, 8, 9 As the presence of actionable BRCA mutations in patients with breast and/or ovarian cancer becomes increasingly important in clinical management decisions, there is increasing support to expand the screening criteria for BRCA mutation testing, including testing for pathogenic mutations in other HR-deficiency genes.
In his review on BRCA testing, Dr Andrew Wallace covers the challenges of BRCA testing from the perspective of a diagnostic laboratory. Demand for BRCA testing is steadily increasing, placing a strain on diagnostics laboratories, particularly in those offering rapid genetic testing at the point of diagnosis. Increasingly, diagnostic laboratories are adopting next-generation sequencing (NGS) technology for BRCA testing, which offers the potential of fast, scalable, cost-efficient and comprehensive sequencing.15, 16, 17, 18, 19 However, the choice and complexity surrounding NGS means that adopting this technology into the diagnostic laboratory requires many considerations, such as selection of an NGS platform, enrichment methods, sequencing chemistries, analytical procedures and techniques for somatic and germline mutation discovery. Interpreting BRCA test results can also be a complex process, involving the assessment of variants of unknown clinical significance, ensuring laboratory results are consistent and clearly reported, and understanding the role of passenger somatic mutations. BRCA testing of formalin-fixed paraffin-embedded tumour samples also presents a number of additional challenges to the diagnostics laboratory, including limited quantity and quality of extracted DNA, and artefactual sequence alterations.20, 21, 22, 23
Genetic counselling is integral to the BRCA testing process. In the final review, Professor Nicoline Hoogerbrugge and Dr Marjolijn Jongmans examine best practices for genetic counselling and BRCA testing, exploring the challenges facing current practice and looking at adapted models of genetic counselling. Current practice in many countries requires face-to-face counselling with a qualified genetics counsellor both prior to, and following, BRCA testing.5, 6 As demand for genetic testing increases, new approaches for delivering genetic counselling may be necessary. It is possible that future BRCA testing and counselling models will incorporate different elements from these new approaches in order to optimise workflow in the era of personalised care. Examples include conserving germline BRCA testing and associated genetic counselling to those patients with a positive tumour pathogenic BRCA mutation result, enabling trained oncologists and medical specialists/staff, in addition to genetic counsellors, to manage pre-test genetic consultations with patients24 and accounting for patient preferences regarding counselling and information such as telephone consultations with additional educational resources for selected patients.25
I greatly appreciate the collaboration of Professor Stoppa-Lyonnet, Dr Andrew Wallace, Professor Nicoline Hoogerbrugge and Dr Marjolijn Jongmans for an engaging symposium and subsequent review articles. We hope that this supplement provides you with a comprehensive update on the practical, prognostic and clinical implications of the evolving BRCA testing landscape.
References
Friedman LS, Ostermeyer EA, Szabo CI et al: Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. Nat Genet 1994; 8: 399–404.
Miki Y, Swensen J, Shattuck-Eidens D et al: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66–71.
Antoniou A, Pharoah PD, Narod S et al: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72: 1117–1130.
Chen S, Parmigiani G : Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007; 25: 1329–1333.
Gadzicki D, Evans DG, Harris H et al: Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet 2011; 2: 53–69.
NICE Clinical Guidelines: NICE Clinical Guidance 164: Familial Breast Cancer. NICE Clinical Guidelines 2013, Available at https://www.nice.org.uk/guidance/cg164.
Audeh MW, Carmichael J, Penson RT et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–251.
Ledermann J, Harter P, Gourley C et al: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014; 15: 852–861.
Tutt A, Robson M, Garber JE et al: Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010; 376: 235–244.
Collins N, McManus R, Wooster R et al: Consistent loss of the wild type allele in breast cancers from a family linked to the BRCA2 gene on chromosome 13q12-13. Oncogene 1995; 10: 1673–1675.
Gudmundsdottir K, Ashworth A : The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006; 25: 5864–5874.
Mao Z, Bozzella M, Seluanov A, Gorbunova V : DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells. Cell Cycle 2008; 7: 2902–2906.
Venkitaraman AR : Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001; 114: 3591–3598.
Rebbeck TR, Mitra N, Wan F et al: Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA 2015; 313: 1347–1361.
Grada A, Weinbrecht K : Next-generation sequencing: methodology and application. J Invest Dermatol 2013; 133: e11.
Idris SF, Ahmad SS, Scott MA, Vassiliou GS, Hadfield J : The role of high-throughput technologies in clinical cancer genomics. Expert Rev Mol Diagn 2013; 13: 167–181.
Loman NJ, Misra RV, Dallman TJ et al: Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30: 434–439.
Mardis ER : Next-generation DNA sequencing methods. Annu Rev Genomics Hum Genet 2008; 9: 387–402.
Walsh T, Lee MK, Casadei S et al: Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing. Proc Natl Acad Sci USA 2010; 107: 12629–12633.
Do H, Dobrovic A : Dramatic reduction of sequence artefacts from DNA isolated from formalin-fixed cancer biopsies by treatment with uracil- DNA glycosylase. Oncotarget 2012; 3: 546–558.
Do H, Wong SQ, Li J, Dobrovic A : Reducing sequence artifacts in amplicon-based massively parallel sequencing of formalin-fixed paraffin-embedded DNA by enzymatic depletion of uracil-containing templates. Clin Chem 2013; 59: 1376–1383.
Wong SQ, Li J, Tan AY et al: Sequence artefacts in a prospective series of formalin-fixed tumours tested for mutations in hotspot regions by massively parallel sequencing. BMC Med Genomics 2014; 7: 23.
Minucci A, Scambia G, Santonocito C et al: Clinical impact on ovarian cancer patients of massive parallel sequencing for BRCA mutation detection: the experience at Gemelli hospital and a literature review. Expert Rev Mol Diagn 2015; 15: 1383–1403.
George A, Smith F, Cloke V et al: Implementation of routine BRCA gene testing of ovarian cancer (OC) patients at Royal Marsden Hospital. Ann Oncol 2014; 25 (Suppl 4): iv307.
Sie AS, van Zelst-Stams WA, Spruijt L et al: More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling. Fam Cancer 2014; 13: 143–151.
Acknowledgements
The supplement was sponsored by AstraZeneca. Medical writing services were provided by Tom Hudson of iMed Comms, Macclesfield, UK and were funded by AstraZeneca.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
EC has received consulting fees, lecture fees and grant support from AstraZeneca.
Rights and permissions
About this article
Cite this article
Capoluongo, E. BRCA to the future: towards best testing practice in the era of personalised healthcare. Eur J Hum Genet 24 (Suppl 1), S1–S2 (2016). https://doi.org/10.1038/ejhg.2016.92
Published:
Issue Date:
DOI: https://doi.org/10.1038/ejhg.2016.92
This article is cited by
-
Germline BRCA 1-2 status prediction through ovarian ultrasound images radiogenomics: a hypothesis generating study (PROBE study)
Scientific Reports (2020)
-
Capillary electrophoresis as alternative method to detect tumor genetic mutations: the model built on the founder BRCA1 c.4964_4982del19 variant
Familial Cancer (2019)
-
High Resolution Melting Analysis is Very Useful to Identify Breast Cancer Type 1 Susceptibility Protein (BRCA1) c.4964_4982del19 (rs80359876) Founder Calabrian Pathogenic Variant on Peripheral Blood and Buccal Swab DNA
Molecular Diagnosis & Therapy (2017)